Clearmind Medicine files US patents for psychedelic combinations

Clearmind Medicine's patent applications

Clearmind Medicine Inc. has announced the publication of three patent applications in the United States, focusing on innovative combinations of psychedelics such as LSD, ketamine, and ibogaine with N-acylethanolamines. These combinations aim to address a range of mental health disorders, including depression, PTSD, and substance use disorders like Alcohol Use Disorder, according to the company's announcement.

Collaboration with NeuroThera Labs

The development of these patent applications is part of Clearmind's collaboration with NeuroThera Labs Inc., which integrates NeuroThera’s palmitoylethanolamide (PEA) technology into Clearmind's therapeutic programs. This partnership has expanded Clearmind's intellectual property portfolio, which already includes numerous patents, by covering combinations of PEA with psychedelic and psychoactive compounds.

Potential therapeutic benefits

Clearmind highlights that these new combinations could offer effective and safer treatment options by possibly reducing the dosage required to achieve therapeutic effects, thereby enhancing tolerability. The company is focused on developing non-hallucinogenic therapies, which aligns with the growing clinical and regulatory interest in psychedelic treatments.

Why it matters

The publication of these patent applications could strengthen Clearmind's position in the biopharmaceutical industry by expanding its intellectual property portfolio. The collaboration with NeuroThera Labs supports the integration of advanced technology into Clearmind's programs, potentially leading to innovative treatment options. As interest in psychedelic therapies grows, Clearmind's approach could offer significant commercial potential.

Clearmind Medicine is a clinical-stage biopharmaceutical company focused on developing non-hallucinogenic psychedelic-derived therapeutics for neuropsychiatric, metabolic, and addiction disorders.